Physician profile
Donna Walker
NPI 1528086964
$3,546.46
in general payments reported to CMS, 2019-2025
26 companies · $118 in 2025
The $118 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $483 · 2020: $266 · 2021: $1,489 · 2022: $646 · 2023: $416 · 2024: $129 · 2025: $118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $297 · Education: $199 · Long Term Medical Supply Or Device Loan: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $296.63 |
| Education | $199.39 |
| Long Term Medical Supply Or Device Loan | $166.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,585.82 | 2019-2023 | |
| Astellas Pharma US INC | $270.54 | 2023-2025 | Vyloy, Xospata |
| E.R. Squibb & Sons, L.L.C. | $191.99 | 2019-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $189.00 | 2020-2021 | |
| Pfizer INC. | $169.09 | 2019-2025 | |
| Eisai INC. | $156.44 | 2019-2022 | |
| Seagen INC. | $109.09 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $98.25 | 2022-2023 | Iclusig |
| Janssen Biotech, INC. | $90.26 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $75.99 | 2019 | |
| Amag Pharmaceuticals, INC. | $75.19 | 2019-2021 | |
| Genzyme Corporation | $72.54 | 2020-2023 | |
| Amgen INC. | $65.40 | 2019-2025 | Evenity, Prolia |
| Merck Sharp & Dohme LLC | $60.01 | 2019-2023 | Keytruda |
| Tesaro, INC. | $54.67 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $49.79 | 2019 | |
| Glaxosmithkline, LLC. | $43.78 | 2020-2021 | |
| Kite Pharma, INC. | $28.49 | 2021 | |
| Taiho Oncology, INC. | $25.10 | 2022 | |
| Exelixis INC. | $24.93 | 2022 | |
| Karyopharm Therapeutics INC. | $23.96 | 2020 | |
| Emd Serono, INC. | $23.45 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $18.68 | 2024 | Lynparza |
| Ipsen Biopharmaceuticals, INC | $16.23 | 2023 | Tazverik, Onivyde |
| Celgene Corporation | $15.85 | 2024 | Reblozyl |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.